Valerio Therapeutics to buy Etherna for €30m; raises €40.25m

Valerio Therapeutics (Euronext Growth Paris: ALVIO) has signed definitive agreements to acquire 100% of Etherna Immunotherapies NV at an enterprise value of €30 million while simultaneously pricing a €40.25 million private investment in public equity to fund the cash portion of the acquisition and the combined company’s development programme.

The PIPE consists of 68,220,333 new Valerio shares issued at €0.59 apiece, a 25% discount to the three-day volume-weighted average price before pricing. The new shares represent approximately 13.7% of Valerio’s pre-financing share capital and voting rights, with settlement expected on August 26.

The acquisition combines Valerio’s targeted-delivery technologies with Etherna’s mRNA chemistry, lipid nanoparticle platforms and GMP manufacturing capabilities. Management wants the enlarged business to control more of the discovery-to-clinical-supply chain internally rather than depending entirely on external RNA manufacturing infrastructure.

Why is Valerio raising more money than Etherna’s enterprise value?

The €40.25 million financing is approximately 1.34 times Etherna’s €30 million enterprise value, immediately showing that the capital raise is not simply a pass-through used to pay the seller.

Part of the acquisition consideration will also be settled in Valerio shares rather than cash. The PIPE therefore provides additional resources for pipeline work, integration, manufacturing expansion and working capital.

Valerio specifically intends to advance VTX-001, VTX-002 and VTX-003, including IND-enabling activities for VTX-001. It also plans to invest in Etherna’s GMP manufacturing operation at Niel in Belgium and integrate research, technical operations and quality functions.

That makes the financing strategically more important than a conventional acquisition funding package. Valerio is effectively recapitalising itself at the same time as it changes its technology platform.

Is the 13.7% PIPE dilution expensive for existing shareholders?

The answer depends on what the new capital creates. Issuing 68.2 million shares expands the pre-financing equity base by approximately 13.7%, meaning existing holders own a smaller percentage of Valerio immediately after settlement.

The €0.59 subscription price also carries a 25% discount to the three-day VWAP. Such discounts are common in biotechnology financings because investors are committing substantial capital to companies with long development timelines and clinical risk, but they still transfer value toward the incoming investors if the existing market price remains higher.

Several existing investors are participating heavily, including Artal International with €18 million, Financière de la Montagne with €7 million and Saint James Luxembourg with €1 million. Their participation provides some alignment between new financing and the existing ownership base.

For shareholders, the proper comparison is therefore dilution versus runway and strategic capability. A smaller percentage of a better-funded integrated RNA platform may be worth more than a larger percentage of an undercapitalised standalone company, but that outcome depends on clinical execution.

What does Etherna add that Valerio could not easily build alone?

Etherna has more than a decade of mRNA and lipid nanoparticle expertise and can manufacture RNA products up to GMP grade. Those capabilities are difficult and expensive to replicate because clinical manufacturing requires validated processes, quality systems, specialised equipment and regulatory compliance.

Valerio’s thesis is that combining nucleic-acid chemistry, lipid nanoparticle delivery and targeted moiety engineering could improve delivery to tissues beyond the liver, a longstanding technical challenge for RNA medicines.

That ambition remains scientific rather than proven commercial performance. Combining complementary platforms does not guarantee that a particular drug candidate will achieve better human efficacy.

However, owning manufacturing capability internally can reduce one operational bottleneck even before clinical efficacy is established. It gives Valerio greater control over development timelines, formulation work and clinical-supply production.

How close is the Etherna acquisition to completion?

The definitive agreements have been signed, but the contribution component still requires approval at an extraordinary general meeting expected around October 6. Existing shareholders representing more than 70% of voting rights have already provided irrevocable commitments supporting the required approval.

That makes shareholder rejection less likely, although completion remains subject to the formal process and customary transaction conditions.

Foreign direct investment clearance had already been obtained before the definitive agreement was signed, removing another potential hurdle.

Valerio’s PIPE settlement is expected earlier, on August 26, meaning the company should receive financing before the acquisition’s shareholder-approval stage is completed.

What will determine whether the transaction creates value?

The first measure will be whether Valerio can integrate Etherna without delaying its existing programmes. Technology combinations can look highly complementary in presentations while creating operational complexity around teams, intellectual property, manufacturing and development priorities.

The second is pipeline progression. Valerio has described an ambition to move programmes through IND-enabling work and toward clinical development, and those milestones will determine whether the enlarged platform is translating technology into drug candidates.

The third is capital efficiency. A €40.25 million PIPE materially strengthens the balance sheet, but RNA therapeutics and GMP manufacturing can consume capital quickly.

Valerio has therefore bought much more than a company with a €30 million enterprise value. It is attempting to create a vertically integrated RNA-development stack financed with a sizeable equity recapitalisation. The investment case depends on whether the additional 13.7% dilution buys enough scientific capability and runway to make that integration commercially meaningful.